Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 137-143 , August 2009

Metronomic Chemotherapy

  • Anthony J. Mutsaers, DVM, DACVIM Oncology

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Anthony J. Mutsaers, DVM, DACVIM Oncology, Division of Molecular and Cell Biology, Sunnybrook Health Sciences Centre, Department of Medical Biophysics, University of Toronto, S-221 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada

References 

  1. Hanahan DJ, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045–1047
  2. Kamen BA. Metronomic therapy: it makes sense and is patient friendly. J Pediatr Hematol Oncol. 2005;27:571–572
  3. Skipper HE, Schabel FM, Mellet LB. Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431–450
  4. Kamen BA, Glod J, Cole PD. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol. 2006;28:325–327
  5. Kamen BA, Rubin E, Glatstein E, et al. High time chemotherapy or high time for low dose. J Clin Oncol. 2000;18:2935–2937
  6. Kerbel RS, Kamen BA. Antiangiogenic basis of low-dose metronomic chemotherapy. Nature Rev Cancer. 2004;4:423–436
  7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186
  8. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195–1206
  9. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–1886
  10. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–R24
  11. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004;64:3994–4000
  12. Bocci G, Nicolaou KC, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–6943
  13. Wang J, Lou R, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13–19
  14. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143–4155
  15. Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell. 2005;8:269–271
  16. Rak J, Yu JL, Kerbel RS, et al. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?. Cancer Res. 2002;62:1931–1934
  17. Bocci G, Francia G, Man S, et al. Thombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917–12922
  18. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570–1574
  19. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573–581
  20. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res. 2005;11:6678–6685
  21. Damber JE, Vallbo C, Albertsson P, et al. The anti-tumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol. 2006;58:354–360
  22. Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of anti-angiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006;12:7444–7455
  23. Rusk A, Cozzi E, Stebbins M, et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-1 peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res. 2006;12:7456–7464
  24. Asahara T, Murahara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–967
  25. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–4346
  26. Bergman PJ. Anticancer vaccines. Vet Clin North Am Small Anim Pract. 2007;37:1111–1119
  27. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648
  28. Biller BJ, Elmslie RE, Burnett RC, et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol. 2007;116:69–78
  29. Walter CU, Biller BJ, Lana SE, et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med. 2006;20:342–347
  30. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002;16:704–709
  31. Ogilvie GK, Vail DM, Klein MK, et al. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Amer Vet Med Assoc. 1991;198(10):1762–1764
  32. Hahn KA, Rohrbach BW, Legendre AM, et al. Hematologic changes associated with weekly low-dose cisplatin administration in dogs. Vet Clin Pathol. 1997;26:29–31
  33. Colleoni M, Rocca A, Sandri MT, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73–80
  34. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs. 2006;17:961–967
  35. Buckstein R, Crump M, Shaked Y, et al. High dose celecoxib and metronomic “low dose” cyclophosphamide is effective and safe therapy in patients with relapsed and refractory aggressive histology NHL. Clin Cancer Res. 2006;12:5190–5198
  36. Vogt T, Hafner C, Bross K, et al. Antiangiogenic therapy with pioglitazone, rofecoxib, and metronomic trofosphamide in patients with advanced malignant vascular tumors. Cancer. 2003;98:2251–2256
  37. Kopp HG, Kanz L, Hartmann JT. Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trophosphamide. Anticancer Drugs. 2006;17:997–998
  38. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosphamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer. 2004;101:2247–2256
  39. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol. 2007;177:2136–2140
  40. Glode LM, Crighton F, Barqawi A, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer. 2003;98:1643–1648
  41. Kong DS, Lee JI, Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006;16:1117–1121
  42. Correale P, Cerretani D, Remondo C, et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep. 2006;16:133–140
  43. Krzyzanowska MK, Tannock IF, Lockwood G, et al. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2007;60:135–141
  44. Mutsaers, AJ, Mohammed, SI, DeNicola, DB, et al: “Metronomic” chemotherapy in veterinary oncology, a pilot study [abstract]. Proceedings of the 21st Veterinary Cancer Society Conference. Baton Rouge, LA, 2001
  45. Mutsaers AJ. Chemotherapy: new uses for old drugs. Vet Clin North Am Small Anim Pract. 2007;37:1079–1090
  46. Lana S, U'Ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007;21:764–769
  47. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med. 2008;22:1373–1379
  48. Charney SC, Bergman PJ, Hohenhaus AE, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc. 2003;222:1388–1393
  49. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–1721
  50. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8:147–156
  51. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65:7045–7051
  52. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99:4349–4354
  53. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low- dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26:76–82
  54. Petit AM, Rak J, Hung MC. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–1530
  55. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9:2755–2768
  56. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22:1301–1309

PII: S1938-9736(09)00020-8

doi: 10.1053/j.tcam.2009.03.004

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 137-143 , August 2009

Article Tools